Analysed CANDEL THERAPEUTICS INC (CADL:NASDAQ) News Sources
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026
yahoo.com
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
17-03-2026
proactiveinvestors.com
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
17-03-2026
yahoo.com
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances
12-03-2026
proactiveinvestors.com
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
12-03-2026
yahoo.com
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
09-03-2026
yahoo.com
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
24-02-2026
yahoo.com
What is the current price of CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The current price of CANDEL THERAPEUTICS INC (CADL:NASDAQ) is $4.89.
CANDEL THERAPEUTICS INC (CADL:NASDAQ) absolute price change since previous trading day?
The absolute price change of CANDEL THERAPEUTICS INC (CADL:NASDAQ) since the previous trading day is $0.06.
CANDEL THERAPEUTICS INC (CADL:NASDAQ) percentage price change since previous trading day?
The percentage price change of CANDEL THERAPEUTICS INC (CADL:NASDAQ) since the previous trading day is 1.2422%.
What is the most recent average sentiment score for CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The most recent average sentiment score for CANDEL THERAPEUTICS INC (CADL:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The most recent sentiment for CANDEL THERAPEUTICS INC (CADL:NASDAQ) is .
SEC-8K** Filing Available For CANDEL THERAPEUTICS INC (CADL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.